CA 111:91114, Yasuda et al, 1989. |
Ronald G. Tilton, et al., Diabetes, Vo. 44, Feb. 1995, "Effects of Vascular and Neural Dysfunction in Streptozocin-Induced Diabetic Rats". |
Mylari B.L., et al., "Novel, potent aldose reductase inhibitors: 3,4-dihydro-4-oxo-3-([5-trifuoromethyl)-Z-benzothiazolyl] methyl-1-phthalazineacetic acid (zopolrestat) and congeners", J. Med Chem 1991 Jan.; 34 (1): 108-22. |
Hosotani, H., et al., "Effects of topical aldose reductase inhbitor CT-112 on corneal sensitivity of diabetic rats", Curr-Eye-Res., 1996 Oct.; 15 (10): 10005-7. |
G. Said, Neuropathies Metaboliques, 1. Diabetic Neuropathies, vol. 141, Rev. Neurol (Paris), No. 11, pp. 683-693, 1985. |
David E. Price, et al., Effect of aldose Reductase Inhibition on Resistance to Ischemic Conduction Block in Diabetic Subjects, vol. 14 No. 5, Diabetes Care, pp. 411-413, May 1991. |
Hitoshi Yasuda, et al., Effect of Prostaglandin E.sub.1 Analogue TFC 612 on Diabetic Neuropathy in Streptozocin-Induced Diabetic Rats, vol. 38, Diabetes, pp. 832-838, Jul. 1989. |
Walter De Gruyter, Glomerukosklerose, diabetische, and Retinopathia diabetica, Pschrymbel, Klinisches, Worterbuch, p. 552 and p. 1325, 257.sup.th edition, 1994. |
Roger C. Bone, et al., Gram-Negative Sepsis: A Dilemma of Modern Medicine, Clinical Microbiology Reviews, Jan. 1993, pp. 57-68, 1993, vol. 6 No. 1. |
Joseph R. Williamson, et al., Hyperglycemic Pseudohypoxia and Diabetic Complicantions, vol. 42, Diabetes, pp. 801-813, Jun. 1993. |